Exploring the $188 Billion Opportunity: Why AI is Set to Transform Global Healthcare by 2030
Avant Technologies has entered a joint venture with Ainnova Tech to form Ai-nova Acquisition Corp (AAC), focusing on AI-powered healthcare solutions. The partnership will commercialize Ainnova's VisionAI platform and retinal cameras in North America and Europe. VisionAI can detect diabetic retinopathy and other diseases through retinal scans with high accuracy. With the global healthcare AI market projected to reach $188 billion by 2030, this venture aims to make retinal scanning a standard in primary care. The technology addresses a critical need, as 30% of 500 million diabetics globally may develop diabetic retinopathy, while there's a shortage of ophthalmologists.
Avant Technologies ha avviato una joint venture con Ainnova Tech per formare Ai-nova Acquisition Corp (AAC), concentrandosi su soluzioni sanitarie alimentate dall'IA. La partnership commercializzerà la piattaforma VisionAI di Ainnova e le fotocamere retiniche in Nord America e Europa. VisionAI è in grado di rilevare la retinopatia diabetica e altre malattie attraverso scansioni retinali con alta precisione. Con il mercato globale dell'IA sanitaria previsto per raggiungere $188 miliardi entro il 2030, questa iniziativa mira a rendere la scansione retinale uno standard nelle cure primarie. La tecnologia risponde a un'esigenza critica, poiché il 30% dei 500 milioni di diabetici a livello globale potrebbe sviluppare retinopatia diabetica, mentre c'è carenza di oculisti.
Avant Technologies ha entrado en una empresa conjunta con Ainnova Tech para formar Ai-nova Acquisition Corp (AAC), centrándose en soluciones de atención sanitaria impulsadas por IA. La asociación comercializará la plataforma VisionAI de Ainnova y cámaras retinianas en América del Norte y Europa. VisionAI puede detectar la retinopatía diabética y otras enfermedades a través de escaneos retinianos con alta precisión. Con el mercado mundial de IA en el sector salud proyectado para alcanzar $188 mil millones para 2030, este esfuerzo busca convertir el escaneo retiniano en un estándar en la atención primaria. La tecnología aborda una necesidad crítica, ya que el 30% de los 500 millones de diabéticos en todo el mundo podría desarrollar retinopatía diabética, mientras que hay una escasez de oftalmólogos.
Avant Technologies는 AI 기반의 의료 솔루션에 집중하기 위해 Ainnova Tech와 합작 투자에 나서 Ai-nova Acquisition Corp (AAC)를 설립했습니다. 이 파트너십은 Ainnova의 VisionAI 플랫폼과 망막 카메라를 북미와 유럽에서 상용화할 것입니다. VisionAI는 망막 스캔을 통해 당뇨병성 망막병증 및 기타 질병을 높은 정확도로 감지할 수 있습니다. 2030년까지 글로벌 헬스케어 AI 시장이 1880억 달러에 이를 것으로 전망되는 가운데, 이 사업은 망막 스캔을 1차 진료의 표준으로 만들기 위해 노력하고 있습니다. 이 기술은 5억 명의 당뇨병 환자 중 30%가 당뇨병성 망막병증을 개발할 수 있다는 점과 안과 의사의 부족이라는 중요한 필요를 해결합니다.
Avant Technologies a formé une coentreprise avec Ainnova Tech pour créer Ai-nova Acquisition Corp (AAC), en se concentrant sur des solutions de santé alimentées par l'IA. Ce partenariat commercialisera la plateforme VisionAI d'Ainnova et des caméras rétiniennes en Amérique du Nord et en Europe. VisionAI peut détecter la rétinopathie diabétique et d'autres maladies grâce à des examens rétiniens avec une grande précision. Avec le marché mondial de l'IA dans le secteur de la santé prévu pour atteindre 188 milliards de dollars d'ici 2030, cette initiative vise à faire de l'examen rétinien un standard dans les soins primaires. La technologie répond à un besoin critique, car 30 % des 500 millions de diabétiques dans le monde pourraient développer une rétinopathie diabétique, alors qu'il y a une pénurie d'ophtalmologistes.
Avant Technologies ist eine Partnerschaft mit Ainnova Tech eingegangen, um die Ai-nova Acquisition Corp (AAC) zu gründen, die sich auf KI-gestützte Gesundheitslösungen konzentriert. Die Partnerschaft wird die VisionAI Plattform von Ainnova und Netzhautkameras in Nordamerika und Europa kommerzialisieren. VisionAI kann diabetische Retinopathie und andere Krankheiten mit hoher Genauigkeit durch Netzhautscans erkennen. Da der globale Markt für KI im Gesundheitswesen voraussichtlich bis 2030 188 Milliarden US-Dollar erreichen wird, soll dieses Unternehmen die Netzhautuntersuchung zum Standard in der Primärversorgung machen. Die Technologie deckt einen dringenden Bedarf, da 30% von 500 Millionen Diabetikern weltweit möglicherweise an diabetischer Retinopathie erkranken könnten, während es einen Mangel an Augenärzten gibt.
- Joint venture formation to commercialize AI healthcare technology in North America and Europe
- Technology addresses large market with 500 million diabetics globally
- Healthcare AI market projected to grow from $6.9B to $67.4B by 2027 (46.2% CAGR)
- Existing commercial agreements with pharma companies, clinics, and insurance companies
- Operating in highly competitive AI healthcare market with tech giants
- Capital requirements responsibility falls on Avant Technologies
Insights
The AI healthcare market projections of
The development of AI-driven sleep tracking and monitoring solutions could provide ResMed with new revenue streams and competitive advantages. With their established market presence in sleep and breathing technologies, they're well-positioned to capitalize on the growing intersection of AI and healthcare. The company's focus on digital health integration demonstrates strategic foresight in an industry rapidly embracing AI-powered solutions.
Issued on behalf of Avant Technologies Inc.
The article continued: The Cleveland Clinic predicts that the healthcare AI sector could reach
Avant Technologies and Ainnova Tech Form Joint Venture to Advance Early Disease Detection Using Artificial Intelligence
Avant Technologies, Inc. (OTCQB: AVAI), an emerging technology company developing solutions in artificial intelligence (AI) infrastructure while exploring additional technologies in the biotechnology and healthcare sectors, today announced it has entered into a Joint Venture and License Agreement with Ainnova Tech Inc. (AINN), a leading healthcare technology (healthtech) company, to form a new Nevada Corporation called "Ai-nova Acquisition Corp" (AAC). The partnership was formed to advance and commercialize Ainnova's technology portfolio, including its "VisionAI" platform and its "Versatile Retinal Cameras."
VisionAI is a cutting-edge, AI-driven platform that can detect diabetic retinopathy and other retinal diseases, as well as diseases unrelated to the retina like cardiovascular disease and potentially even Alzheimer's with high accuracy and speed using retinal scans. Meanwhile, Ainnova's next-generation versatile retinal cameras are seamlessly integrated with VisionAI for precise retinal scans. Along with the VisionAI software, Ainnova's retinal cameras, offer AAC SaaS + retinal camera commercialization opportunities with opticians and eye care centers in two extremely profitable markets,
"This joint venture aligns perfectly with our long-term goals, and as we work together to push the boundaries of what's possible in the healthtech sector, we look forward to setting new standards and bringing transformative solutions to patients around the world in an accessible way," said Vinicio Vargas, CEO of Ainnova.
Ainnova will contribute to AAC its proprietary technology portfolio, including VisionAI and its retinal camera technology, and the licensing rights for AAC to develop, maintain, and commercialize the technology portfolio in both
Ainnova and Avant's partnership seeks to make retinal scanning a new standard in primary care and basic health services by diagnosing a host of diseases early through a simple visual test that AAC can offer as a scalable and accessible solution.
With over 500 million people living with diabetes globally, VisionAI is designed to detect the early markers of diseases like diabetic retinopathy, which is the leading cause of blindness among working age adults. Over
Unfortunately, there aren't enough ophthalmologists globally. And
According to Ainnova, the diagnostic error rate in diabetic retinopathy is about
This partnership makes sense for Avant and its shareholders given the AI in healthcare market is projected to grow from
CONTINUED… Read this and more news for Avant Technologies Inc. https://usanewsgroup.com/2023/10/26/unlocking-the-trillion-dollar-ai-market-what-investors-need-to-know/
Other recent industry developments and happenings in the market include:
HEALWELL AI, Inc. (TSX: AIDX) (OTCQX: HWAIF), a healthcare technology company focused on AI and data science for preventative care, and WELL Health Technologies Corp. (TSX: WELL) (OTCQX: WHTCF), a digital healthcare company focused on positively impacting health outcomes by leveraging technology to empower healthcare practitioners and their patients globally, recently announced an expansion to their multi-year strategic alliance agreement to develop an AI-enhanced clinical trials program to accelerate innovation and improve patient outcomes. Leveraging the country's largest network of primary and specialty care clinics, with over 180 clinics and thousands of healthcare practitioners, HEALWELL and WELL will collaborate to expand clinical trial access to more patients than ever before.
"Launching and managing clinical trial sites at WELL's clinic locations across
For WELL, hosting trials within its clinics will transform them into hubs of innovation, directly benefitting patients by bringing experimental treatments to local sites and improving accessibility. Leveraging HEALWELL's Contract Research Organization (CRO) capabilities alongside WELL's clinic infrastructure positions the partnership as a formidable player in AI-driven clinical trials, fostering the potential for new revenue.
"Patient identification and recruitment for clinical trials has become an increasingly complex challenge in the global healthcare and life science sectors," said Dr. Alexander Dobranowski, CEO of HEALWELL. "Success hinges not only on identifying patients but also on effectively recruiting them and managing their participation – steps that lead to improved outcomes for patients, practitioners and the healthcare system as a whole. Through our established late stage CRO, Canadian Phase Onward, HEALWELL has already made significant strides in accelerating the recruitment process, but the growing network of WELL clinics is an opportunity for us to execute our plans at scale. Ultimately, this service will be a benefit to doctors, healthcare practitioners and patients alike while reducing the cost of clinical trials and shortening their timelines."
ResMed Inc. (NYSE: RMD), the world's leading health technology company focused on sleep, breathing, and care delivered in the home, recently announced new patient-centric designed to enhance the therapy journey for sleep apnea patients. The new innovations integrate with digital wearable devices and generative artificial intelligence designed to deliver a more personalized sleep health experience and improve overall health.
"We know that digital wearables and other innovative technologies like AI can help consumers better understand their sleep habits and create a personalized pathway to better rest," said Carlos M. Nunez, M.D., Chief Medical Officer at ResMed. "Regular sleep tracking can offer crucial insights that empower people to make informed decisions about improving their sleep quality both now and in the future."
Clover Health Investments, Corp. (NASDAQ: CLOV), a physician enablement technology company committed to bringing access to great healthcare to everyone on Medicare, recently reported strong Q3 2024 financial results which included
"Underpinned by our ability to use technology to empower any physician on a wide network, our results position us to drive membership growth while maintaining strong underlying financial performance," said Andrew Toy, CEO of Clover Health. "I am proud that, powered by Clover Assistant, our health plans are anchored on identifying and managing diseases as early as possible to better control the total cost of care."
Clover Assistant is the company's software platform designed to aggregate patient data from across the healthcare ecosystem to support clinical decision-making and improve health outcomes through the early identification and management of chronic disease. The Clover Assistant AI tool was made available to payers and providers in late May of this year.
CONTACT:
info@usanewsgroup.com
(604) 265-2873
DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances.
View original content:https://www.prnewswire.com/news-releases/exploring-the-188-billion-opportunity-why-ai-is-set-to-transform-global-healthcare-by-2030-302302545.html
SOURCE
FAQ
What is the joint venture between Avant Technologies and Ainnova Tech called?
What is the projected size of the healthcare AI market by 2030?
What diseases can VisionAI detect through retinal scans?
What is the current diagnostic error rate in diabetic retinopathy?
